Biglycan holds great potential as biomarker as deregulated levels of soluble biglycan are detected in a variety of inflammatory and chronic disease, such lupus nephritis (144), diabetes (162, 163), fibrosis (164), renal diseases (159), and cancer (165), biglycan holds great potential as biomarker. This evidence concerns the gene BGN and diabetes mellitus.